Synergy Pharmaceuticals (SGYP) Shares are Down -8.93%

Synergy Pharmaceuticals (SGYP) has risen sharply, recording gains of 14.95% in the past 4 weeks. However, the stock has corrected -8.93% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 15.19% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 0.45% and the fifty day Moving Average is 12.01%. Synergy Pharmaceuticals, Inc. is up 30.28% in the last three month period. Year-to-Date the stock performance stands at -17.28%.

Synergy Pharmaceuticals (SGYP) : The consensus price target for Synergy Pharmaceuticals (SGYP) is $10.75 for the short term with a standard deviation of $6.01. The most optimist securities analyst among the 2 who monitor the stock believes that the stock can reach $15, however, the pessimist price target for the company is $7.


Synergy Pharmaceuticals (NASDAQ:SGYP): stock turned positive on Friday. Though the stock opened at $4.39, the bulls momentum made the stock top out at $4.74 level for the day. The stock recorded a low of $4.39 and closed the trading day at $4.69, in the green by 7.08%. The total traded volume for the day was 3,344,747. The stock had closed at $4.38 in the previous days trading.

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *